Hepion to present CRV431 preclinical data at liver congress

Hepion Pharmaceuticals

Hepion Pharmaceuticals (NASDAQ:HEPA) will present a poster on CRV431’s antifibrotic activity at the Digital International Liver Congress 2020, taking place from Aug. 27-29.

Dr. Joseph Kuo will present a preclinical study evaluating CRV431’s ability to reduce hepatic fibrosis and fatty diet-induced body weight gain in a mouse model of non-alcoholic steatohepatitis (NASH).

The company is currently conducting a Phase 2a study, called ‘AMBITION’, to assess the safety, tolerability, and pharmacokinetics of CRV431 administered to NASH patients for 28 days.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.